CHEPLAPHARM Arzneimittel GmbH


This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.


Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

1st December 2022
Earnings Call Q3 2022 Results
29th November 2022
Publication Quarterly Report Q3 2022
1st September 2022
Earnings Call H1 2022 Results
29th August 2022
Publication 1st Half-Year Report 2022
2nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit


The latest from CHEPLAPHARM

By taking over the product rights for DORMICUM® and LEXOTAN®, CHEPLAPHARM closes the very successful fiscal year 2018

"As a perfect addition to an already extremely positive year for CHEPLAPHARM, we were able to start another large project in 2018 with F. Hoffmann-La Roche, with whom we maintain a long-established business relationship. With the Closing taking place in January 2019, we will successfully conclude this project", CEO Sebastian F. Braun sums up, pleased about the acquisition of the two known drugs.

"This means that we fully reached all our milestones, especially in terms of sales and earnings. We are very satisfied with what we have achieved and take this as an incentive to continue managing and advancing our company in a powerful and goal-oriented manner."

DORMICUM® (Midazolam) is a prescription drug used for sedation before or during diagnostic and therapeutic procedures. With the transaction, CHEPLAPHARM has acquired market authorisations in approximately 70 countries.

LEXOTAN® (Bromazepam) is prescribed for the treatment of anxiety, tension and other somatic or psychiatric conditions associated with anxiety syndrome in approximately 80 countries worldwide.

2018 was in every respect more than successful and can be classified as the most profitable year in the company history. This includes, in particular, the number of new products and the extensive investments based on a new, solid financing structure, the successful integration of more than eighty new employees and the start of construction works for the expansion of our German company headquarters in Greifswald (#cpugrade).

Press Office:
CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | presse(at)

Investor Relations topics

Back to top expand_less